Get all premium features to the best stock analysis tool

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that on August 5, 2026, the Company received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on May 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company's Class A ordinary shares had been below $1.00 per share for 30 consecutive business days.